Aug 13, 2026 | Legal Compliance
In 2025, the Fifth Circuit’s Zyla Life Sciences, LLC v. Wells Pharma of Houston, LLC included a passing, non-binding comment suggesting that brand-name manufacturers might sue compounders under state unfair-competition laws for selling unapproved “new...
Aug 13, 2026 | Legal Compliance, News
Eli Lilly & Co. has significantly escalated its legal campaign against the illicit trade of its investigational weight-loss drug, retatrutide. The pharmaceutical giant filed lawsuits in federal court against six U.S.-based businesses—including medical spas,...
Aug 7, 2026 | Legal Compliance, News
Driven by booming consumer demand for anti-aging, weight-loss, and performance-enhancing therapies, integrative clinics, medical spas, and online vendors have rushed to offer popular compounds like BPC-157 and TB-500. Two recent developments expose a dangerous gap...
Aug 3, 2026 | Legal Compliance, News
If your medical spa or aesthetic practice relies on major dermal filler brands, a major legal filing in federal court deserves your attention. On July 21, 2026, Allergan, Inc. and its parent company, AbbVie, filed a patent-infringement lawsuit against Galderma Group...
Jul 31, 2026 | Legal Compliance, State-Specific Regulations
Beginning August 26, 2026, Ohio providers who offer laser and light-based hair removal services will be subject to a revised legal framework. House Bill 377 amends Ohio Revised Code Section § 4731.33 and enacts a new companion section, § 4731.331, both of which govern...
Jul 13, 2026 | Legal Compliance
If you follow wellness, anti-aging, or fitness trends, you’ve probably heard of peptides like BPC-157 or TB-500. Often marketed online as “miracle molecules” for healing injuries and turning back the clock, these compounds are currently at the center of a massive...
